New Clot-Busting device tested in tiny stroke study
NCT ID NCT05074186
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study tested a new device designed to remove blood clots from the brain in people having a severe stroke. Eight patients were treated within 8 hours of symptoms starting. Researchers measured how well the device restored blood flow and tracked any serious side effects for 90 days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- neurological thrombectomy device
- What this could lead to
- If successful, this device could offer a new option to quickly remove clots and restore blood flow in stroke patients.
- What could go wrong
- This was a very small study (8 people) with no comparison group, so results may not apply broadly. The device also carries risks like bleeding or vessel damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
8 people
The number who actually took part.
- Started
-
Jun 2021
- Finished
-
Jul 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: at least 18 years of age at time of consent Has baseline National Institutes of Health Stroke Scale (NIHSS) ≥ 8; Able to be treated within 8 hours of stroke symptom onset or Last Known Normal (LKN); Exclusion Criteria: Cannot provide consent or legally authorized representative not available to provide consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
kaledia Health/Buffalo General Medical Center/GVI
Buffalo, New York, 14203, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a checklist and heart monitor stop repeat strokes?
- Heart hole or stroke trigger? global registry tracks who gets closure and what happens next
- Two ways to catch a hidden heart rhythm after stroke
- Blood test may reveal who recovers after a stroke
- Can a smart bracelet and app stop a second stroke?
- Pharmacist and coach team takes aim at blood pressure after stroke